NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ALKEM · data 2026-11-01
Alkem Laboratories Ltd.
In plain words
Price: 13.8% below its 52-week high of ₹5,933.5.
Delivery: 54.2% of traded shares were kept for delivery over the last 10 sessions, against 56.5% over the last 60.
Latest results: a net profit of ₹520 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹15,081 cr |
| Net profit (last 12 months) | ₹2,158 cr |
| Sales growth, 3 years (yearly) | 8.2% |
| Profit growth, 3 years (yearly) | 32.7% |
At a glance
Promoters 53.0%, pledged 0.0%, institutions 30.9%.
P/E 28.4, dividend yield 1.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 17.8%, ROCE 17.8%, operating margin 17.5%: how much profit it earns on the money it uses.
Debt/equity 0.15, Profit growth 32.7% and sales growth 8.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 32.7% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ALKEM Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹3,740.15 crore.
Net profit was ₹519.96 crore.
Operating margin was 20.5%.
EPS was ₹43.49.
ALKEM के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹3,740.15 करोड़।
शुद्ध मुनाफ़ा: ₹519.96 करोड़।
ऑपरेटिंग मार्जिन: 20.5%।
EPS: ₹43.49।
ALKEMના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹3,740.15 કરોડ.
ચોખ્ખો નફો: ₹519.96 કરોડ.
ઓપરેટિંગ માર્જિન: 20.5%.
EPS: ₹43.49.
Written from the filed numbers. Not a recommendation.
Smart-money activity
29/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 61.0% over the last 20 sessions vs 55.8% in the 40 before (1.09x); shares delivered per day 0.98x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 22 schemes hold it, about ₹2,054 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 1/15: Verdict "None", sustained score 33/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results ● Dividend
- 1 Sept 26Insider SAST disclosure: HDFC Mutual Fund acquired 25,019 shares -2.2% next session
- 14 Aug 26Results Q1 FY27 results: net profit ₹520 cr -1.4% next session
- 7 Aug 26Dividend Dividend ₹10 (ex-date) 0.0% next session
- 20 Feb 26Dividend Dividend ₹43 (ex-date) +2.1% next session
- 8 Aug 25Dividend Dividend ₹8 (ex-date) -0.6% next session
- 14 Feb 25Dividend Dividend ₹37 (ex-date) +1.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹3,740 cr | ₹520 cr | — | 20.5% | 43.49 |
| Jun 2023 | ₹2,968 cr | ₹287 cr | — | 13.1% | 23.98 |
| Sept 2022 | ₹3,079 cr | ₹331 cr | — | 14.7% | 27.67 |
Shareholding trend
| Holder | Jun 2025 | Sept 2024 |
|---|---|---|
| Promoters | 53.04% | 55.66% |
| Foreign institutions (FII) | 9.11% | 9.02% |
| Domestic institutions (DII) | 21.80% | 19.21% |
| Mutual funds | 16.67% | 14.94% |
| Retail investors | 1.35% | 1.39% |
| Number of shareholders | 79,740 | 74,744 |
Common questions
What was Alkem Laboratories Ltd.'s latest quarterly profit?
Alkem Laboratories Ltd. reported a net profit of ₹520 cr for the quarter ended Jun 2026, on revenue of ₹3,740 cr.
How much do promoters hold in Alkem Laboratories Ltd.?
Promoters held 53.04% of Alkem Laboratories Ltd. at the end of Jun 2025, with 0.00% of promoter shares pledged.
Is Alkem Laboratories Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.15.
What is Alkem Laboratories Ltd.'s P/E ratio?
About 28.4, based on the last 12 months' earnings and a price of ₹5,113.5 (data 2026-11-01).
What is the 52-week high and low of Alkem Laboratories Ltd.?
The 52-week high is ₹5,933.5 and the 52-week low is ₹4,811.
Mutual funds holding Alkem Laboratories Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 22 schemes holding about ₹2,054 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Large and Midcap Fund | SBI Mutual Fund | 1.88% | ₹761 cr |
| Nippon India Growth Mid Cap Fund | Nippon India Mutual Fund | 1.27% | ₹637 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.82% | ₹167 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 3.76% | ₹131 cr |
| NIPPON INDIA VALUE FUND | Nippon India Mutual Fund | 0.95% | ₹81 cr |
| NIPPON INDIA RETIREMENT FUND - WEALTH CREATION SCHEME | Nippon India Mutual Fund | 2.26% | ₹66 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 3.16% | ₹55 cr |
| ADITYA BIRLA SUN LIFE MIDCAP FUND | Aditya Birla Sun Life Mutual Fund | 0.83% | ₹54 cr |
| Nippon India ETF Nifty Midcap 150 | Nippon India Mutual Fund | 0.77% | ₹29 cr |
| Nippon India Nifty Midcap 150 Index Fund | Nippon India Mutual Fund | 0.77% | ₹21 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.68% | ₹18 cr |
| Mirae Asset Nifty Midcap 150 ETF | Mirae Asset Mutual Fund | 0.77% | ₹14 cr |
| SBI Nifty Midcap 150 Index Fund | SBI Mutual Fund | 0.77% | ₹10 cr |
| ADITYA BIRLA SUN LIFE NIFTY MIDCAP 150 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 0.77% | ₹4 cr |
| ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF | Aditya Birla Sun Life Mutual Fund | 2.77% | ₹2 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd. | ₹5,113.5 | ₹61,277 cr | 28.4 | — | 17.8% | 17.8% | 0.15 | -7.7% |
| Glenmark Pharmaceuticals Limited | ₹2,298.7 | ₹65,137 cr | 36.1 | — | 14.1% | 29.2% | 0.06 | +24.1% |
| Biocon Limited | ₹351.8 | ₹57,310 cr | 104.6 | 1.6 | 1.4% | 3.5% | 0.45 | -7.4% |
| Abbott India Limited | ₹25,635 | ₹54,384 cr | 33.7 | — | 34.5% | 39.1% | 0.04 | -14.2% |
| Gland Pharma Ltd. | ₹3,095.9 | ₹51,112 cr | 45.2 | — | 10.5% | 12% | 0.03 | +62.6% |
| IPCA Laboratories Limited | ₹1,927.8 | ₹48,898 cr | 37.3 | — | 15.2% | 16.3% | 0.1 | +49.5% |
Compare ALKEM with GLENMARK in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ALKEM in NSE Scanner →